Santa Monica, CA, 26 January 2017 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be attending Sachs Associates 10th Annual European Life Sciences CEO Forum & Exhibition being held on 6th-7th March, 2017 at the Hilton Zurich Airport Hotel, Switzerland. […]
http://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00adminhttp://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngadmin2017-01-26 19:05:452017-03-06 14:02:57Sachs Associates 10 Annual European Life Sciences CEO Forum & Exhibition, 2017
25 January 2017 SCRIP Emerging Company Profile: University spinout, Trethera – which recently signed a licensing deal to develop Nanotherapeutics Inc.’s ribonucleotide reductase inhibitor Triapine – believes it is the first company to target cancer nucleotide metabolism through a combination approach. Read Article
Santa Monica, CA and Alachua, FL, January 5, 2017 – Trethera Corporation and Nanotherapeutics, Inc. today announced the signing of an exclusive worldwide agreement whereby Nanotherapeutics has granted Trethera an exclusive license for the global development, manufacturing and marketing of Triapine® (3-AP) and all formulations, for the treatment of hematological malignancies. Triapine® is a clinical-stage, […]
http://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00adminhttp://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngadmin2017-01-05 13:19:532017-01-05 13:20:23Trethera Corporation and Nanotherapeutics Sign Exclusive Worldwide Agreement for Rights to Triapine® in Hematological Malignancies
November 27, 2017 – Trethera Corporation will be attending the American Society of Hematology (ASH) Annual Meeting in Atlanta from December 9-12, 2017. Trethera is preparing for initiation of a Phase 1 clinical trial in myelodysplastic syndrome (MDS) for its small molecule, deoxycytidine kinase inhibitor, TRE-515.
http://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Adminhttp://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngAdmin2017-11-27 19:57:472017-11-27 19:58:12Trethera attending the 59th ASH Annual Meeting in Atlanta
September 7, 2017 – Trethera, a biotechnology company developing innovative small molecule inhibitors of cancer nucleotide metabolism, will be attending the BioPharma America conference in Boston, MA, September 26-27, 2017.
http://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Adminhttp://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngAdmin2017-09-07 20:43:392017-11-18 23:20:00Trethera at BioPharm America
September 7, 2017 – Trethera, a biotechnology company developing innovative small molecule inhibitors of cancer nucleotide metabolism, will be attending RESI Boston 2017 on September 26, 2017.
http://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Adminhttp://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngAdmin2017-09-07 20:39:112017-11-18 23:20:38Trethera to attend RESI Boston 2017